Evidence suggests that allogenic hematopoietic cell transplantation (HCT) improves overall survival in patients with myelodysplastic syndrome (MDS), a serious blood disorder, when compared with best available supportive care. But MDS is a heterogeneous disease and questions remained about how cancer-related genetic mutations influence outcomes.
This study, led by Dana-Farber researcher R. Coleman Lindsley, MD, Ph.D., used DNA sequencing to evaluate samples from a large clinical study of HCT in older parents with MDS led by Corey Cutler, MD, MPH. The findings are published in theThe researchers integrated the genetic and clinical characteristics of each patient in their analysis. They determined that patients had the potential to benefit from HCT regardless of their.
Oncologists have debated the value of HCT for patients with high-risk MDS with TP53 mutations. Outcomes for these patients have historically been so poor that some have wondered whether HCT might be a futile procedure.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
New analysis finds stigma stopping evidence-based response to drug overdoses in UKA new analysis in the BMJ argues that UK government opposition to drug consumption rooms is rooted in societal stigma
Læs mere »
The evidence seen during Lucy Letby's murder trial, from handwritten notes to cards for parentsThe lengthy trial of the UK's most notorious child killer featured an enormous amount of detail, with the prosecution using handwritten notes, documents and even a sympathy card penned by Letby as evidence of her sinister presence on the Countess of Chester neonatal unit.
Læs mere »
Douglas Ross out of step with global evidence on drug policy, charity warnsDOUGLAS Ross has been branded 'out of step' with global evidence on drug policy by a charity chief after a series of claims on…
Læs mere »